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Introduction
Approximately 8–18% of all patients with high blood pressure (BP)
are apparently resistant to drug treatment.1,2 In this situation, new
strategies to help reduce BP are urgently needed but the complex
pathophysiology of resistant hypertension makes this search difficult.
Not surprisingly in this context, the latest non-drug treatment which
triggered controversy is catheter-based renal denervation (RDN).3,4
The method uses radiofrequency energy, or alternatively ultrasound
or chemical denervation, to disrupt renal nerves within the renal
artery wall, thereby reducing sympathetic efferent and sensory affer-
ent signalling to and from the kidneys.5,6 Various experimental
modelsof hypertension strongly support this concept7,8 and available
evidence also suggests that sympathetic nervous system activation
contributes to the development and progression of hypertension
and subsequently to target organ damage.7– 11 Historical observa-
tions have shown that surgical sympathectomy can reduce BP as
well as morbidity and mortality in patients with uncontrolled hyper-
tension.12,13 However, the clinical evidence in support of RDN
as an effective interventional technique in patients with resistant
hypertension is conflicting. A number of observational studies and
three randomized, controlled trials (Symplicity HTN-2, Prague-15,
and DENERHTN) support both safety and efficacy of this new
therapy14– 22 but some smaller studies and the large, single-blind, ran-
domized, sham-controlled symplicity HTN-3 trial failed to show su-
periority of RDN when compared with medical therapy alone.23–25
Whatever the shortcomings of individual trials may be, the possi-
bility remains that the observed BP responses were due to placebo
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response, the Hawthorne effect, regression to the mean, unknown
co-interventions or other bias.26 The design, conduct, and interpret-
ation of the trials in RDN have been discussed extensively else-
where.27– 30 Accordingly, since the publication of the Symplicity
HTN-3 results, some health care providers have been unwilling to
endorse RDN in the absence of incontrovertible efficacy data.
However, current evidence also seems equally insufficient to
declare the technology a proven failure. Whenever doubts arise
around the effectiveness of new treatment approaches, an assess-
ment by rigorously designed studies is necessary to furnish conclusive
evidence. With this controversy in mind, a multidisciplinary European
Expert Group has convened on 9 December 2014 to assess the
current gaps in our knowledge about RDN, unmet needs and
where clinical trials may best be focused in the future. The current
document represents a summary of the main conclusions of this clin-
ical consensus conference. The topics are divided into three sections:
procedural aspects, patient populations, and design considerations
for future clinical trials.
Procedural aspects
In the years, since the first studies on RDN, our view of the technique
has significantly evolved.31 –34 Far from being a simple procedure that
could be performed with little training by any interventionist regard-
less of their subspecialty, it is now recognized as a complex, specia-
lized therapy whose primary and secondary success depends on a
large number of influencing factors and uncertainties that may not
be filled by our current knowledge. Moreover, there are a number
of different systems, methods, and strategies currently employed in
RDN (using uni- or bipolar radiofrequency energy, high-energy ultra-
sound and chemical ablation), which make it difficult to standardize
treatment recommendations and compare different treatment
modalities in patients.
The European Expert Group agreed that several procedural
aspects need to be considered for future clinical trials, as they
would help to improve reliability and thereby efficacy of the denerv-
ation technique:
(i) Preclinical studies to assess the safety and efficacy of any RDN
system are currently performed in healthy, normotensive
animals.Our knowledgeof peri-arterial renalnervedistribution
in chronically hypertensive patients is very limited and it is
unclear how far preclinical results can be applied to vessels
subject to atherosclerosis. A suitable, hypertensive animal
model would greatly help to answer open questions and to
compare the different available catheters in terms of both
surrogate markers (e.g. histological renal nerve ablation, renal
norepinephrine content) and BP effects.
(ii) The optimal degree of contact against the renal artery wall and
the depth, location, duration, and intensity of energy delivery to
provide the best procedural results are still being investigated.
An extensive human autopsy study has shown the large vari-
ation in distribution and density of the renal sympathetic
nervous system in the adventitia of renal arteries (Figure 1)33:
thehighest averagenumberofnerveswasobserved in the prox-
imal and middle segments of the renal artery and the lowest in
the distal segments. Additionally, the mean distance from the
lumen to the nerve was much longer in proximal than in distal
segments. These human and other preclinical observations
suggest that asymmetric and most probably distal renal artery
targeting is required to achieve effective ablation of renal sym-
patheticnerves.34,35 However, inmanyof the clinical trials there
was no specific advice on how to apply energy and thus inter-
ventionists did not specifically treat in this area, potentially
thereby reducing the efficacy of the procedure.28
(iii) The degree of RDN has been documented by norepinephrine
spillover before and 30 days after the procedure in a small
subgroup of 17 patients.36 The response to RDN was 40% on
average, but was highly variable, ranging from 0 to 80%.
Such a variability of treatment effects has also been documen-
ted in preclinical studies in pigs, when four radiofrequency abla-
tions were applied in the main renal artery.28 The application of
radiofrequency energy post-bifurcation has been shown to
reduce variability in treatment effects in pigs. It should be
kept inmind that, if distal ablationmay improve theeffectiveness
of RDN, it should also not increase the risk of the procedure.
However, the occurrence of distal RDN-induced renal artery
stenosis (RAS), if any, may be more challenging to revascularize
byangioplasty, stentingor surgery. Further, the proximity to the
ureter and other soft tissue need be considered.
(iv) Maximum procedural efficacy would also mean the achieve-
ment of ablation in all four quadrants, the whole circumference,
of both renal arteries. In Symplicity, this was achieved in only a
small proportion of patients (,30%). A post hoc analysis indi-
cated that per-protocol bilateral 4-quadrant RDN was asso-
ciated with the greatest reductions in office, home and
ambulatory systolic BP.29 Low-pressure balloon catheters
designed for RDN20,37 may achieve a more complete and
reproducible circumferential ablation with less between-
interventionists procedural variability, but head-to-head com-
parisons of available catheters are lacking.
(v) There appears to be a ‘dose–response’ dependency between
the number of ablation attempts and the efficacy of renal
nerve ablation in both post hoc clinical and prospective preclin-
ical investigations.29 However, the minimum and maximum ‘ef-
fective dose’ of energy delivery and ablation attempts at the
individual level remains to be determined precisely, although
there is no simple way to assess it in humans.
(vi) The feasibility, need and consequences of treating small
renal arteries (,4 mm), accessory, polar or segment arteries
remains to be clarified. Indeed, some of these small arteries
cannot be treated by the available catheters. The new emerging
systems may need modification of their profile to enable better
and safer access to renal arteries of different calibre. Further-
more, induction of a de novoRAS or progression of pre-existing
RAS after RDN and long-term vascular safety need to be care-
fully investigated.38,39
(vii) The lack of reliable markers of procedural success to immedi-
ately establish on time whether denervation has been com-
pletely achieved in a specific patient remains the major unmet
need. As a result, it is uncertain if the negative trials arise from
sub-optimal application of the technology or if the technique,
even when optimally applied, does not work. A number of effi-
cacy markers have been explored but there is no consensus on
F. Mahfoud et al.2220
their usefulness, even when indices of sympathetic control,
such as baroreflex function, has been taken into account.40
Some early studies indicated that noradrenaline levels or
electrical stimulation of the renal artery may correlate with ab-
lation efficacy,41,42 but this would need confirmation in larger
studies and besides the latter is associated with pain and sub-
stantial discomfort to patients.
Patient population
Catheter-based RDN has been investigated and used primarily as a
last resort in patients with resistant hypertension (defined as systolic
BP ≥160 mmHg, ≥150 mmHg in diabetes mellitus while on a
regimen of ≥3 anti-hypertensive drugs of different classes, including
a diuretic, at maximal or highest tolerated dose).1,3 The rationale was
the great need to lower BP and thereby cardiovascular events in
high-risk patients lacking suitable alternative treatments, as these
patients are per definition resistant to standard drug treatment.1
Renal denervation was not developed to replace the ongoing anti-
hypertensive treatment. Standardized evaluation of patients referred
to specialized hypertension clinics because of apparent resistant
hypertension, has shown that this patient group is characterized
by a variable mix of conditions not necessarily likely to exhibit the
greatest response to RDN therapy.18,43 Indeed, the high prevalence
of target organ damage, including renal fibrosis and vascular stiffness,
which are difficult to reverse, renders BP control difficult to achieve
whatevermethods areused. Moreover, in these patients, the ongoing
oral anti-hypertensive treatment prescribed by the physicians in a
variable and non-reproducible manner and taken by the patients in
a variable and non-reproducible manner remains a major confound-
ing factor to analyse precisely the true BP effect of any procedure.
Therewas an extensive and controversial discussion within the Euro-
pean Expert Group, which patients will have the highest likelihood to
benefit from RDN.
Identification of the appropriate patient
population
To improve the efficacy of RDN, the procedure needs to be targeted
upon a population with high probability of BP response. This is com-
plicated by (i) the complex pathophysiology of hypertension,
Figure 1 Cumulative distribution of nerves at distance from lumen before the bifurcation (A), divided into proximal, middle, and distal segments
(B), and divided into ventral, dorsal, superior, and inferior regions (C). With permission from Sakakura et al.33
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especially resistant hypertension, (ii) the lack of clinically applicable,
reliable, easy, and reproducible measures of ‘increased sympathetic
activity’ that could be used to guide treatment decisions, and (iii)
the absence of pre-procedural useful predictors of the long-term
BP response following RDN. Although the importance of renal
nerve signalling in hypertension has been shown by a number of
studies in humans,8,10 there are many factors besides sympathetic
nervous system activation that can drive increases in BP. To date,
there is no clearly established link between sympathetic nervous
system activity and response to RDN44,45; however, this does not ne-
cessarily mean that the concept is mistaken. Rather an appropriate in-
vestigative method to quantify precisely and reliably the central
sympathetic activity in humans with such a precision to delineate pre-
dictive parameters in each individual patient is missing. Clearly, there
is a need for more research on this topic. A caveat with the above dis-
cussion is therefore that there is currently insufficient evidence to
conclude that reducing sympathetic activity to the kidneys would
inevitably reduce BP in patients with increased sympathetic nervous
system activity.
Isolated systolic hypertension (ISH), defined as office systolic BP
≥140 mmHg and diastolic BP ,90 mmHg is the pre-dominant
hypertensive subtype in elderly patients.46,47 ISH is characterized
by an increased aortic stiffness, increased pressure wave reflections,
and low pulse pressure amplification.48 Data indicate that ISH is asso-
ciated with limited response to RDN,49,50 as it could be expected
from drug trials. Accordingly, increased central pulse pressure indi-
cate of aortic stiffness is related to worse BP response after
RDN.50 Furthermore, patients who failed to respond to RDN exhib-
ited striking BP lowering in the ROX Coupler Study,51 suggesting that
targeting arterial stiffness rather than sympathomodulation would be
a superior approach in such patients.
Methodology and clinical trials
Any new trial in RDN needs to undoubtedly demonstrate that the
technology is actually effective, i.e. that catheter-based RDN
reduces the generally accepted surrogate marker BP. The European
Expert Group did not attempt to design a comprehensive clinical trial
protocol in detail. The discussion did focus on a number of salient
methodological points that need to be taken into consideration
and identified open questions as follows.
What is the most suitable patient
population?
Patients with resistant hypertension currently considered eligible
for RDN therapy may not be the population most likely to respond
with the greatest decrease in BP. Also, it is challenging to find a suffi-
cient number of proven, treatment-resistant severely hypertensive
patients for an adequately powered trial.22 An alternative may be
to run a trial in younger patients with milder forms of hypertension.
This would have several advantages. First and foremost, younger
patients tend to have greater sympathetic nervous system activation
than older patients.52,53 Secondly, the arterial wall in younger, less
severely hypertensive patients might be more responsive to RDN-
induced changes in sympathetic tone since vascular remodelling is
still in a reversible state. Reducing pill burden might be of particular
benefit in this young population. However, it is deemed necessary
to consider potential concerns when treating patients with mild
stages of hypertension (e.g. to take the risk-benefit ratio into
account). Indeed, a new trial in severe resistant hypertension
would not pose ethical concerns, since there are only limited other
therapeutic alternatives.51,54 In contrast, patients with mild to mod-
erate hypertension have safe and well-established alternatives to an
invasive procedure and may respond well to such conservative treat-
ment. A way to ensure an ethical conduct would be to include the
option of patient’s preference in the study design. The European
Expert group favoured the inclusion of patients with moderate
rather than resistant hypertension as preferred population to be
studied next. Whichever the degree of hypertension is chosen,
there is widespread consensus among the Expert group that patients
with ISH or severe grade III chronic kidney disease (CKD) (defined
as eGFR ,30 mL/min/1.73 m2) should be excluded from the proof
of concept (phase II) and phase III efficacy trials. Impaired renal
function is also currently considered a contraindication for RDN,
due to safety issues.3 Nephrologists within the Experts Group
argued for applying RDN in CKD based on a very strong pathophy-
siologic rationale55 and preliminary clinical data.56 –59
Should there be a washout period?
A medication washout period is often recommended in the design of
clinical trials to allow the BP to return to pre-treatment levels.60
However, the European Expert Group considered this to be un-
acceptable for further studies of RDN in resistant hypertensive
patients. In general, patients with high BP on multiple drugs should
not be subjected to washout as this is well known to be associated
with increased risk for events, in particular stroke.61,62 Conceptually,
a washout period may be acceptable in patients treated with one or
two drugs provided strict regimens for escape algorithms would be
applied in order to assess the ‘pure’ effect of RDN on BP. There
was wide agreement within the Expert group that washout should
only be performed, if at all, by highly experienced investigators and
research centres familiar with drug withdrawal algorithms.22
Should ambulatory blood pressure be the
primary end point instead of office blood
pressure?
Twenty-four hourambulatoryBPmonitoring (ABPM)provides more
precise BP profiles when compared with office BP, since it provides
the average of a large number of readings performed during normal
conditions of life but also during nocturnal rest.63– 65 Several
studies documented better prognostic value of ambulatory over
office BP in different populations.66–70 In patients with resistant
hypertension, the use of ABPM is considered mandatory for exclu-
sion of pseudo-resistance due to ‘white-coat’ effect.1,3,4 The BP re-
duction induced by any anti-hypertensive treatment largely differs
when the measurement are performed by office or ABPM and the
extent of the discrepancies depends on the BP values at baseline
and the degree of white-coat reaction.67,71 The absence of ABPM
as the efficacy measure has been noted as a weakness of many
trials in RDN,26,72 except for the DENERHTN study which success-
fully used change in daytime mean ambulatory systolic BP as the
primary endpoint.22 The Expert group was strongly in favour of
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ambulatory BP as the primary measure of response to RDN but also
as inclusion criterion for a number of reasons. Ambulatory BP mon-
itoring is less susceptible to bias and placebo effect than office-based
measurements,64,73 can be easily analysed blind to the allocation of
treatment, and allows improved selection of patients for the proced-
ure, as patients with white-coat hypertension will unlikely show any
effect on 24-h BP.17 Importantly, ambulatory BP is an independent
predictor of outcome70,74 and hence a valid end point. The only
weakness is the lack of evidence-based recommendations for target
BPbasedonambulatory values, although theESHhas provided thresh-
old for normal ambulatory BP levels,64 but this is of minor importance
since the magnitude of decrease in ambulatory BP is the primary study
objective. The Expert group considered a reduction of 5 mmHg in
daytime systolic BP as a clinical meaningful reduction, which might be
used for sample size calculations. In order to reduce between-patients
variability and thus the standard deviation around the expected differ-
ence, ABPM should be standardized (validated devices, appropriate
cuff, timing with regards of the last intake of anti-hypertensive drugs,
number of BP measurements, etc.) according to international guide-
lines64 and optimally analysed by a blinded core lab.
How should adherence with
anti-hypertensive therapies be measured
and ensured?
Non-adherence to treatment is frequent in ‘resistant’ hypertensive
patients.75,76 It has been speculated that lack of standardized treat-
ment and sub-optimal adherence before as well as after denervation
may have confounded the results of earlier studies.26 In any further
trial, it will be essential to standardize the concomitant therapies
and to at least evaluate or even optimize adherence. Given the
doubts around the efficacy of RDN,23 adherence criteria in patients
receiving multiple anti-hypertensive drugs may well need to be stric-
ter than in apharmacological trial, although it is very difficult toensure
and assess adherence properly.77 Furthermore, there are no strat-
egies to improve medication adherence that have been demon-
strated to be of long-term benefit. Directly observed therapy
where patients take their drugs in the presence of a healthcare pro-
fessional,78 has been successfully used in smaller RDN studies but
may be difficult to implement in a large-scale multicentre trial.24,28
Today, there are multiple ways of assessing drug adherence in
patients but only few of them are really accurate and the most accur-
ate one are difficult to implement in clinical practise.79,80 However,
the option to include adherence-promoting programmes and com-
pliance assessment in a trial design seems worth exploring. Electronic
pill dispensers record each opening of a pill container over weeks or
months and thus may provide an account of the regularity of drug
intake and represent an attractive tool for future studies in the
field, but this method does not guarantee that the patient has
indeed taken the treatment.81 Consensus has been reached that at
least meticulous monitoring of adherence is required in future
trials. This would at least allow adjusting the results for this major
confounder.
Is a sham procedure necessary?
The use of a sham procedure and the associated unmasking of a
placebo effect has been suggested as the reason for the lack of
observed benefits from RDN in symplicity HTN-3.82 Sham proce-
dures can reduce possible placebo and Hawthorne effects;
however, their use does not eliminate other sources of bias such as
variations in treatment score and dosages prescribed by the physi-
cians and adherence to treatment by the patients. The Expert
group questions and expressed serious concerns, whether a sham
procedure would be necessary in a trial of resistant hypertensive
on standardized treatment and if adherence variability can be mini-
mized with ambulatory BP as the primary end point. In addition, the
risk to patients from the sham procedure should be taken into
consideration. In the case of RDN, this risk is not negligible and the
use of invasive sham is possibly unethical in mild to moderate hyper-
tensive patients, although probably most adequate to be implemen-
ted in this patient population. A sham procedure might be acceptable
if it consists only of general anaesthesia and puncture of the groin
with no use of renal angiography (which would expose patients
to radiation, contrast dye unnecessarily and the risk of selective
renal arteriography).
Handling of concomitant medication
The European Expert Group had a clear opinion on standardization
of concomitant therapy. A longer stable run-in period with un-
changed adequate combination of anti-hypertensive drugs, including
a maximal dose of diuretic and at best a renin–angiotensin system
blockerand acalcium channel blockerof at least4–8weeksappeared
to be appropriate. There was contention about whether all patients
need to be switched onto the same treatment regimen prior to RDN
to reduce between-subject variability, as done in the DENERHTN
trial.22 It remains to be disputed whether all patients should be on
mineraloreceptor antagonist or at least should have been exposed
to this drug class before RDN is considered. The prescription of a
4th line of anti-hypertensive treatment, such as spironolactone,
may decrease BP but would make the recruitment still more difficult.
Moreover, the addition of one morepill on top of manyothers before
entry into the trial may influence compliance to treatment. Unani-
mously, strict standardization of the anti-hypertensive treatment
appeared to be the key.
Health economics issues: impact on the
clinical pathway
There have been several publications on the economic evaluation of
RDN for the treatment of resistant hypertension.83– 85 These publi-
cations rely on Markov models applied on the very positive results of
Symplicity HTN-2,15 which allow the extrapolation of systolic BP
changes on reduction in cardiovascular endpoints. The models
used are very similar and yield consistent results in terms of gain in
quality adjusted life years of 1-year gain over patient’s lifetime.
The economic studies use extrapolation models, which all assume
that the reduction in systolic BP obtained by RDN are (i) sustainable
and (ii) associated with the same decrease in events as reduction
induced by drug treatment in the course of randomized trials. Both
assumptions can be challenged by the fact that effectiveness of a
drug investigated in a trial is higher compared with real life situa-
tions.86,87 In addition, these models ignore the costs of setting-up
an outpatient clinic to screen and select hypertensive patients, who
are eligible for RDN.83–85,88 It is, however, debatable whether
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these costs should be included if RDN is undertaken only in high
volume centres with established hypertension clinics while low
volume centres are excluded for both efficacy and efficiency
reasons. The European Expert Group established that several
health economics issues shouldbe addressed in future clinical studies:
(1) Individual patients’ pathways flow charts for information about
patients screened in hypertension clinics are needed.
(2) Models need to be re-analysed when data on adverse event oc-
currence and on the sustainability of BP reduction are available.
(3) Consistent data collection for resource utilization needs to be
ensured.
Summary and outlook
A number of important questions still need to be addressed in order
to establish an evidence base for RDN that would permits its adop-
tion for routine clinical use (Box 1). Much of the unmet need distils
down to the issue of standardization. This applies to the technology
and the technique, where different systems may not work equally
well in all situations. It applies to the terminology used, as well as to
markers of procedural success. And perhaps most of all, standardiza-
tion will be key when designing clinical trials. Treatments, popula-
tions, methods, and adherence measures need to be highly
consistent to avoid inconclusive or biased results. Finally, we urgently
need to delineate predictors of BP response following RDN. Only
then we will be able to individualize patient care and even expand
this intervention to specific hypertension patient groups. The open
questions around RDN touch upon a large number of specialties
from interventional cardiologists to hypertension experts and
molecular biologists. The future of the therapy will depend on
closer interactions at all levels, necessitating smaller projects target-
ing specific questions as well as large-scale multidisciplinary research
programmes. RDN may or may not be a breakthrough therapy.
Focused, collaborative high-quality research will be necessary to
ensure that future patients are neither denied an effective therapy
nor needlessly put at risk from procedures that bring no benefits.
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Box 1: Recommendations for future randomized
controlled trials on renal denervation in hypertension
Study population
† Include patients with moderate rather than resistant hypertension
reflecting the pathogenetic importance of sympathetic activity in
earlier stages.
† Exclude patients with stiff large arteries (e.g. isolated systolic
hypertension) for the next pivotal trial.
Study design
† Perform wash out period only in highly experienced centers
(safety concerns).
† Consider sham procedure with renal angiography as potentially
unethical in mild to moderate hypertension.
† Standardize concomitant antihypertensive therapy (preferentially
all treated with the combination of a RAS-blocker, calcium channel
blocker and diuretic in the run-in period).
† Monitor drug adherence as potential confounder of blood
pressure response (e.g. pill counting, electronic pill dispensers,
toxicological drug analysis).
Study outcomes
† Use change in ambulatory blood pressure as the primary efficacy
endpoint (strictly standardized), while change in office blood
pressure should be considered as secondary parameter.
† Delineate clinically easy accessible predictors for blood pressure
efficacy.
† Incorporate health-economic analysis beyond the
Markov-models.
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Fulminant lymphocytic myocarditis mimicking ST-elevation myocardial
infarction
Marco Amoruso*, Stefano Muzzarelli, Tiziano Moccetti, and Giovanni Pedrazzini
Department of Cardiology, CardioCentroTicino, via Tesserete 48, Lugano 6900, Switzerland
* Corresponding author. Tel: +41 766 101 284, Fax: +41 918 053 154, Email: marco.amoruso@cardiocentro.org
A 74-year-old lady with hypertensive cardiomyop-
athy and COPD (GOLD II) was admitted to our
hospital because of angina and worsening dyspnoea
over the last 3 days. The admission electrocardio-
gram showed ST-elevation and Q waves in the
antero-lateral leads, compatible with subacute
anterior myocardial infarction. Troponin I was
52 mg/L and CK 2061 U/L. Urgent coronary angiog-
raphy excluded coronary artery disease, so trans-
thoracic echocardiography (TTE) and cardiac
magnetic resonance (CMR) were performed. TTE
showed diffuse in left ventricular hypokinesia and
increased thickness of the antero-septal wall,
while CMR revealed a corresponding extensive
myocardial oedema and necrosis with predominant
sub-epicardial/mid-myocardial distribution highly
suggestive of a myocarditis pattern. The diagnosis
of fulminant lymphocytic myocarditis was con-
firmed by myocardial biopsy. The ejection fraction
dropped from 45 to 15% but recovered 3 weeks
later (temporary ECMO support) until 40%.
Panel A: ST-elevation in V1–V4 and DI–aVL leads
(red boxes), admission ECG. Panel B: significative
QRS widening and diffuse ST-elevation (yellow
boxes), day 4 ECG. Panels C, D and F: short-axis (C)
and three-chamber long-axis (D) MR T2 mapping
with extensive circumferential sub-epicardial myo-
cardial oedema, particularly on the right-ventricular side of the interventricular septum (green arrows; the light purple myocardium
marks myocardial oedema with T2 value increased to 68 ms). Three-chamber, long-axis MR late enhancement view (Panel F) with an analo-
gous distribution of myocardial necrosis (blue arrows). Panel E: myocardial biopsy showing diffuse lymphocytic–histiocytic infiltrate and
myocyte necrosis.
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